Novartis sees first patient death following Gilenya treatment; Baxter to buy Synovis Life Technologies;

  @FiercePharma: SEC accuses Stiefel Labs, ex-chief of fraud: NYT. News | Follow@FiercePharma

> Novartis ($NVS) has reported a multiple sclerosis patient died after starting treatment with Gilenya. It hasn't been confirmed or excluded whether the drug played a role in the death. News

> Baxter ($BAX) has announced an agreement to buy Synovis Life Technologies ($SYNO)--a provider of biological and mechanical products for soft tissue repair--for $28 per share, which equates to $325 million of equity value or approximately $260 million after adjusting for the net cash. Baxter release

>The U.S. Court of Appeals for the Federal Circuit vacated a preliminary injunction that prohibited Mylan from launching a generic version of a Doryx 150 mg product before a decision at trial, Warner Chilcott ($WCRX) announced. Warner Chilcott release

> Citing alleged breach of contract, Napo Pharmaceuticals has terminated its 2005 collaboration agreement with Glenmark Pharmaceuticals through which the latter was to develop and commercialize crofelemer in more than 140 countries. The compound is a treatment for both acute and chronic watery diarrhea. Napo release

> India's Jubilant Life Sciences plans to pump $20 million into an expansion of its Eastern Shore facility and add jobs, Maryland Gov. Martin O'Malley said Monday. Item

Biotech News

@FierceBiotech: Leave it to engineers to come up with a potentially novel solution to fight Alzheimer's disease. Article | Follow @FierceBiotech

@JohnCFierce: Quintiles sets up a China CRO, plans to double staff in China--another step in the shift to the East. News | Follow @JohnCFierce

@RyanMFierce: Avila makes progress with Btk inhibitor, same type of drug as $JNJ shelled out $150M for last week. Story | Follow @RyanMFierce

@MaureenFierce: Fooling immune system reverses multiple sclerosis in mice, according to a University of Freiburg study. More | Follow @MaureenFierce

@MarkHFierce: Look at this--gene therapy works! Sometimes the most interesting news comes out during the weekend. Item | Follow @MarkHFierce

> Catabasis boosts Series A to $47.6M as it zeroes in on Amarin rival. News

> Cambridge, MA startup snags $20M for therapeutic vaccine program. Article

> Alexza shares spike after antipsychotic wins weak embrace from FDA panel. Story

Biotech Research News

> Antibody may help fight Alzheimer's. More

> Protein 'switch' could be key to fighting obesity, diabetes. Story

> Gene therapy appears to work for hemophilia B patients. Report

> Supreme Court considering crucial gene patent case. News

Pharma Manufacturing News

> Actavis, Mylan continue defense in Digitek API suits. Article

> Packaging veteran urges including patient in drug pedigree chain. More

> KV reports doubt about viability under decree. News

> Europe issues 2nd recall of drugs made by Ben Venue. Story

And Finally... When India's Kayem sent sodium thiopental to the U.S. early this year, it thought it was a good business decision. But its drug was being injected into prisoners on death row for their execution in the prisons of Nebraska and South Dakota. "When we learnt it was being used for execution in U.S. prisons it was a total bouncer. We issued a public statement announcing that we have discontinued selling it to them," Managing Director Navneet Verma told The Hindu. Report

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…